Initial evaluation of a canine stifle arthrotomy post-operative pain model

Tomas, Andrea; Bledsoe, David; Wall, Sabrina; Davidson, Gigi; Lascelles, B. Duncan X.

doi:10.1016/j.tvjl.2015.03.010

Cited by 14 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies in mice and rats demonstrated an analgesic effect of 48–72 hr duration following a single s.c. injection of different SR‐buprenorphine compounds (Carbone, Lindstrom, Diep, & Carbone, ; Chum et al., ; Clark, Clark, & Hoyt, ; Foley, Liang, & Crichlow, ; Healy et al., ; Jirkof, Tourvieille, Cinelli, & Arras, ; Kendall et al., ). Similar SR‐buprenorphine compounds have been used in dogs (Nunamaker et al., ; Tomas, Bledsoe, Wall, Davidson, & Lascelles, ), cats (Catbagan, Quimby, Mama, Rychel, & Mich, ; Enomoto et al., ; Johnson et al., ), rabbits (DiVincenti, Meirelles, & Westcott, ), Göttingen minipigs (Thiede et al., ), guinea pigs (Smith, Wegenast, Hansen, Hess, & Kendall, ), sheep (Gatson, Pablo, Plummer, & Granone, ; Walkowiak & Graham, ; Zullian et al., ), alpaca (Dooley et al., ), elephant seals (Molter et al., ), and macaques (Nunamaker et al., ). However, the SR‐buprenorphine formulations used in these studies were either unknown or compounded products and, in most of these studies, the authors reported skin lesions at the site of injections, ranging from simple s.c. nodules to abscesses, open wounds, and necrotic lesions likely caused by the viscosity of the product or the formulation matrix (Carbone et al., ; Catbagan et al., ; Clark et al., ; DiVincenti et al., ; Foley et al., ; Molter et al., ; Nunamaker et al., , ; Thiede et al., ).…”

Section: Introductionmentioning

confidence: 99%

“…| 503 Tomas, Bledsoe, Wall, Davidson, & Lascelles, 2015), cats (Catbagan, Quimby, Mama, Rychel, & Mich, 2011;Enomoto et al, 2017;Johnson et al, 2017), rabbits (DiVincenti, Meirelles, & Westcott, 2016), Göttingen minipigs (Thiede et al, 2014), guinea pigs (Smith, Wegenast, Hansen, Hess, & Kendall, 2016), sheep (Gatson, Pablo, Plummer, & Granone, 2015;Walkowiak & Graham, 2015;Zullian et al, 2016), alpaca (Dooley et al, 2017), elephant seals (Molter et al, 2015), and macaques (Nunamaker et al, 2013).…”

mentioning

confidence: 99%

See 1 more Smart Citation

The pharmacokinetics and analgesic effects of extended‐release buprenorphine administered subcutaneously in healthy dogs

Barletta

Ostenkamp

Taylor

et al. 2018

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

Buprenorphine is a partial μ agonist opioid used for analgesia in dogs. An extended-release formulation (ER-buprenorphine) has been shown to provide effective analgesia for 72 hr in rats and mice. Six healthy mongrel dogs were enrolled in a randomized, blinded crossover design to describe and compare the pharmacokinetics and pharmacodynamics of ER-buprenorphine administered subcutaneous at 0.2 mg/kg (ER-B) and commercially available buprenorphine for injection intravenously at 0.02 mg/kg (IV-B). After drug administration, serial blood samples were collected to measure plasma buprenorphine concentrations using liquid chromatography/mass spectrometry detection. Heart rate, respiratory rate, body temperature, sedation score, and thermal threshold latency were recorded throughout the study. Median (range) terminal half-life, time to maximum concentration, and maximum plasma concentration of ER-buprenorphine were 12.74 hr (10.43-18.84 hr), 8 hr (4-36 hr), and 5.00 ng/ml (4.29-10.98 ng/ml), respectively. Mild bradycardia, hypothermia, and inappetence were noted in both groups. Thermal threshold latency was significantly prolonged compared to baseline up to 12 hr and up to 72 hr in IV-B and ER-B, respectively. These results showed that ER-buprenorphine administered at a dose of 0.2 mg/kg resulted in prolonged and sustained plasma concentrations and antinociceptive effects up to 72 hr after drug administration.

show abstract

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

The pharmacokinetics and analgesic effects of extended‐release buprenorphine administered subcutaneously in healthy dogs

Barletta

Ostenkamp

Taylor

et al. 2018

Vet Pharm & Therapeutics

View full text Add to dashboard Cite

show abstract

“…Additionally, the assessment tools that have been produced thus far have been developed for client-owned cats, not research cats. Although there is no data on this subject, our observations are that research cats are less demonstrative than client-owned cats and other unpublished observations indicate these subjective tools are less sensitive in research cats than client-owned cats, similar to the situation in dogs [22]. …”

Section: Discussionmentioning

confidence: 76%

“…Evaluation of an extended release formulation of buprenorphine in dogs undergoing arthrotomy provided pain relief over a 72 h period [22]. In cats, it has been reported that the administration of a single dose of ER-Bup had a similar efficacy (as evaluated by subjective pain assessment scales) and adverse effect profile as twice-daily oral transmucosal administration of buprenorphine [23].…”

Section: Introductionmentioning

confidence: 99%

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

et al. 2016

View full text Add to dashboard Cite

BackgroundNon-steroidal anti-inflammatory drugs (NSAIDs), transdermal fentanyl patches, and transmucosal buprenorphine are probably the most commonly used options for providing post-operative analgesia in the early at-home period. However, these require daily administration or are associated with abuse concerns. One of the significant unmet needs in veterinary surgery and pain management is for longer acting opioids for cats to effectively bridge the gap between the in-hospital and at-home recovery periods.A proof of concept study of an extended release formulation of buprenorphine HCL (ER-Bup) was conducted using objective kinetic measures and a unilateral onychectomy model. Using a blinded, randomized, two period crossover design, four cats were allocated to control (saline) or ER-Bup (0.6 mg/kg, subcutaneously [SC]) treatment groups. All animals underwent a unilateral forelimb onychectomy per period with a washout/recovery period in between. Observational pain scores and kinetic data (using a pressure sensitive walkway [PSW]) were collected prior to (baseline) and at intervals for 72 h following surgery. Symmetry indices were derived for kinetic variables (peak vertical force [PVF]; vertical impulse [VI]) of each forelimb for landing following a jump and for walking. A rescue analgesic protocol was in place. Effect of surgery and treatment were evaluated using a mixed model statistical approach.ResultsNo cats required rescue analgesics based on subjective pain score. ER-Bup had a positive influence on subjective pain scores during the 72 h postsurgery (p = 0.0473). PVF and VI of the operated limb were significantly decreased for both landing (p < 0.0001 and p < 0.0001) and walking (p < 0.0001 and p < 0.0001 respectively) compared to control. ER-Bup resulted in significantly decreased asymmetry in limb use during landing (PVF, p < 0.0001; VI, p < 0.0001) and walking (PVF, p = 0.0002, VI, p < 0.0001). The novel use of data collected following a jump from an elevated platform appeared to provide all desired information and was easier to collect than walking data.ConclusionThis study demonstrates that SC administration of ER-Bup may be an effective analgesic for a 72 h period postoperatively. Furthermore, landing onto a PSW from an elevated perch may be a useful and efficient way to assess analgesics in cats using a unilateral model of limb pain.Electronic supplementary materialThe online version of this article (doi:10.1186/s12917-017-0943-5) contains supplementary material, which is available to authorized users.

show abstract

“…Limb use can be objectively measured through static or dynamic weight distribution using force plates or pressure sensitive walkways (2). In veterinary medicine, such objective measures have been used in evaluation of surgical interventions, the determination of analgesic efficacy, development of surgical models for pain, and effective monitoring of patients in rehabilitation programs (3)(4)(5)(6)(7).…”

Section: Introductionmentioning

confidence: 99%

Repeatability and accuracy testing of a weight distribution platform and comparison to a pressure sensitive walkway to assess static weight distribution

Bosscher¹,

Tomas²,

Roe³

et al. 2017

Vet Comp Orthop Traumatol

View full text Add to dashboard Cite

show abstract

Initial evaluation of a canine stifle arthrotomy post-operative pain model

Cited by 14 publications

References 14 publications

The pharmacokinetics and analgesic effects of extended‐release buprenorphine administered subcutaneously in healthy dogs

The pharmacokinetics and analgesic effects of extended‐release buprenorphine administered subcutaneously in healthy dogs

Pilot evaluation of a novel unilateral onychectomy model and efficacy of an extended release buprenorphine product

Repeatability and accuracy testing of a weight distribution platform and comparison to a pressure sensitive walkway to assess static weight distribution

Contact Info

Product

Resources

About